Anthropic Brings Novartis CEO Vas Narasimhan Onto Its Board

Anthropic just made a move that signals where they think AI’s biggest real-world impact will come from. The company’s Long-Term Benefit Trust has appointed Vas Narasimhan, CEO of Novartis, to its Board of Directors.

Narasimhan isn’t your typical tech board member. He’s a physician-scientist who’s been running one of the world’s largest pharmaceutical companies. Under his watch, Novartis has pushed through more than 35 novel medicines through regulatory approval processes that make software certification look like a walk in the park.

“Vas brings something rare to our board,” said Daniela Amodei, Anthropic’s co-founder and president. “Getting powerful new technology to people safely and at scale is what we think about every day at Anthropic. Vas has been doing exactly that for years.”

This is higher than I expected in terms of governance significance. With Narasimhan’s appointment, Trust-appointed directors now hold a majority on Anthropic’s board. That’s a structural shift worth paying attention to.

For those who haven’t been following Anthropic’s weird corporate structure: the Long-Term Benefit Trust is an independent body whose members have no financial stake in the company. Its sole job is to keep Anthropic balanced between making money and sticking to its public benefit mission of developing AI for the long-term benefit of humanity. No financial interest, just a mandate.

Neil “Buddy” Shah, who chairs the Trust, put it plainly: “Vas has spent his career stewarding breakthrough science responsibly — exactly the perspective we are excited to have on the board as we develop consequential technology.”

Narasimhan’s background is genuinely relevant here. Early in his career, he worked on HIV/AIDS, malaria, and tuberculosis programs across India, Africa, and South America. He’s an elected member of the US National Academy of Medicine and serves on Harvard Medical School’s board of fellows. This isn’t someone who just talks about global health — he’s been in the trenches.

“Working across medicine, innovation, and global health has shown me the transformative potential of technology when deployed responsibly,” Narasimhan said. “In healthcare, AI is accelerating solutions to some of the hardest scientific challenges, from deepening our understanding of disease biology to designing better medicines.”

Anthropic’s board now includes Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, Chris Liddell, and Narasimhan. It’s a solid mix of tech, finance, and now deep healthcare experience.

I’ve been watching how AI companies handle governance, and this appointment feels different from the typical “let’s add a famous name” board move. Narasimhan has actually navigated the tension between breakthrough science and regulatory reality at massive scale. That’s exactly the kind of perspective Anthropic needs as they push Claude into more regulated industries.

The healthcare angle is obvious but worth stating: if AI is going to transform medicine, the companies building it need people who understand what “safe and effective” actually means in a clinical context. Narasimhan brings that.

Anthropic also recently opened a Sydney office and named Theo Hourmouzis as GM for Australia and New Zealand. The company is clearly scaling up its global presence while simultaneously tightening its governance structure. These moves together suggest they’re thinking long-term about both reach and responsibility.